Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 19/20 | 1.00 |
| ▸ | PTPN2 | P17706 | 18/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 18/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 6/20 | 0.69 |
| ▸ | HSPE1 | P61604 | 6/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31701131 | 0.81 | PTPN1 (1.00) | PTPN5PTPN2PTPN1HSPD1HSPE1 | |
| SCHEMBL2245939 | 0.81 | PTPN5 (0.86) | PTPN5PTPN2PTPN1HSPD1HSPE1 | |
| SCHEMBL31701139 | 0.81 | PTPN5 (1.00) | PTPN5PTPN2PTPN1HSPD1HSPE1 | |
| SCHEMBL6084269 | 0.78 | PTPN5 (0.63) | PTPN5PTPN2PTPN1HSPD1HSPE1 | |
| SCHEMBL31701723 | 0.78 | PTPN1 (0.71) | PTPN5PTPN2PTPN1HSPD1HSPE1 | |
| SCHEMBL2243342 | 0.78 | PTPN1 (1.00) | PTPN5PTPN2PTPN1HSPD1HSPE1 | |
| SCHEMBL6086240 | 0.76 | PTPN5 (0.61) | PTPN5PTPN2PTPN1HSPD1HSPE1 | |
| SCHEMBL6086154 | 0.76 | PTPN5 (0.60) | PTPN5PTPN2PTPN1HSPD1HSPE1 | |
| SCHEMBL2246107 | 0.76 | PTPN5 (0.70) | PTPN5PTPN2PTPN1HSPD1HSPE1 | |
| SCHEMBL2245164 | 0.75 | PTPN5 (0.89) | PTPN5PTPN2PTPN1HSPD1HSPE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319056-A1 | METHODS FOR TREATING CANCER | UNIV INDIANA TRUSTEES (US) | 2025-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319056-A1 | METHODS FOR TREATING CANCER | HSP90AB1, HSP90B1, HSP90AB2P | PTPN5 2831/4885PTPN2 2771/4885PTPN1 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.